Please login to the form below

Not currently logged in

eye disease

This page shows the latest eye disease news and features for those working in and with pharma, biotech and healthcare.

ReNeuron set for recovery after Woodford stake sale

ReNeuron set for recovery after Woodford stake sale

There should be additional results this year from a phase 2a trial of its human retinal progenitor cell (hRPC) therapy for inherited, degenerative eye disease retinitis pigmentosa, which already has positive

Latest news

More from news
Approximately 8 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    43% complete responses indicating the disease had disappeared entirely. ... Another of its partners, Horizon Therapeutics recently submitted to the FDA the Genmab-developed teprotumumab for the treatment of active thyroid eye disease.

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    to learn from its own mistakes with therapies for Huntington’s disease and also haemophilia. ... Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close

  • Pharma deals during March 2013 Pharma deals during March 2013

    However, ophthalmology is increasingly an area of interest in the industry with potential for growth as the global population ages; it is estimated that around 25m people have dry eye disease ... 175. SARcode Bioscience/ Shire. Acquisition. SAR 1118 for

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    There is a growing demand for eye care, owing to the rising prevalence of eye disease, an ageing global population and increased demand for healthcare in emerging markets. ... This is demonstrated by the fact that rare disease research is central to its

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • What are you doing, Dave?

    parents. Google's DeepMind is exploring the use of AI in managing head and neck cancer, acute kidney injury, and detection of eye disease. ... An AI system has been shown to make referral decisions on eye diseases with 94% accuracy, matching the

  • 'Fake news': battling misinformation in healthcare

    The article is entitled ‘Alzheimer’s disease can be spotted through simple eye test’ and whilst this article is based on  genuine research, it is  far too early to be making ... As a result, the public was misinformed about a very serious and

  • emotive adds to medical team with new Scientific Lead and Associate Medical Writer

    Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease, ... emotive is an

  • The power of observation in gathering patient insights

    For example, we recently conducted a multi-country research project for a rare eye disease. ... Patients walked us around their homes; sharing with us stories about life before and after their disease, adding significant layers of insight to the findings

  • PAN trio run for charity

    RP is an inherited disease of the eye, where the light sensitive cells of the retina cease to function and die away. ... However, the research being undertaken at Moorfields Eye Hospital hopes to slow or even reverse this disease by injecting cells from

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...